Last reviewed · How we verify
Havrix™-based investigational formulation
Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Prevention of hepatitis A infection.
At a glance
| Generic name | Havrix™-based investigational formulation |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Havrix contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses, leading to the production of protective anti-HAV antibodies. This investigational formulation likely represents a modified or enhanced version of the established Havrix vaccine, potentially with improved immunogenicity, stability, or dosing schedule. The vaccine prevents infection by hepatitis A virus through antibody-mediated neutralization.
Approved indications
- Prevention of hepatitis A infection
Common side effects
- Injection site soreness or swelling
- Headache
- Fatigue
- Myalgia
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Havrix™-based investigational formulation CI brief — competitive landscape report
- Havrix™-based investigational formulation updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI